Antidiabetic Biosimilars Market - Global Industry Insights, and Opportunity Analysis, 2016-2024
Antidiabetics help control blood glucose levels in diabetic patients. Various types of antidiabetics include biguanides, thiazolidinediones, DPP-IV inhibitors, α-glucosidase Inhibitors, sulfonylureas, insulin, and GLP-1 receptor agonists such as exenatide. A biosimilar product is biological product that is approved on the basis that it is highly similar to a FDA approved biological product known as a reference product. Biosimilar manufacturers need to generate data from lab testing and clinical testing to demonstrate that the biosimilar developed provides the same therapeutic benefit to patients as the reference product.
Antidiabetics help control blood glucose levels in diabetic patients. Various types of antidiabetics include biguanides, thiazolidinediones, DPP-IV inhibitors, α-glucosidase Inhibitors, sulfonylureas, insulin, and GLP-1 receptor agonists such as exenatide. A biosimilar product is biological product that is approved on the basis that it is highly similar to a FDA approved biological product known as a reference product. Biosimilar manufacturers need to generate data from lab testing and clinical testing to demonstrate that the biosimilar developed provides the same therapeutic benefit to patients as the reference product.
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
© Coherent market <strong>Insights</strong>. All Rights Reserved<br />
<strong>Antidiabetic</strong> <strong>Biosimilars</strong> <strong>Market</strong> -<br />
GLOBAL INDUSTRY INSIGHTS, TRENDS,<br />
OUTLOOK, AND OPPORTUNITY ANALYSIS, <strong>2016</strong>-<br />
<strong>2024</strong>
REPORT DESCRIPTION<br />
<strong>Antidiabetic</strong> <strong>Biosimilars</strong> <strong>Market</strong> – Overview<br />
<strong>Antidiabetic</strong>s help control blood glucose levels in diabetic patients. Various types of antidiabetics include biguanides, thiazolidinediones,<br />
DPP-IV inhibitors, α-glucosidase Inhibitors, sulfonylureas, insulin, <strong>and</strong> GLP-1 receptor agonists such as exenatide. A biosimilar product<br />
is biological product that is approved on the basis that it is highly similar to a FDA approved biological product known as a reference<br />
product. Biosimilar manufacturers need to generate data from lab testing <strong>and</strong> clinical testing to demonstrate that the biosimilar developed<br />
provides the same therapeutic benefit to patients as the reference product.<br />
Patent expiries to drive growth of the global antidiabetic biosimilars market<br />
The global antidiabetic biosimilars market is driven by increasing number of diabetes mellitus patients. According to World Health<br />
Organization (WHO) the number of people suffering from diabetes stood at 422 million in 2014. The global prevalence of diabetes<br />
among adults above 18 years increased to 8.5% in 2014 from 4.7% in 1980. Increasing incidence of lifestyle disorders such as obesity,<br />
increases the risk of diabetes <strong>and</strong> in turn drives growth of the antidiabetic biosimilars market. In June 2014, the European Medicines<br />
Agency authorized the first biosimilar of insulin Glargine, Abasaglar from Eli Lilly <strong>and</strong> Company <strong>and</strong> Boehringer Ingelhim International<br />
Gmbh, for treatment of diabetes mellitus. The biosimilar received U.S. FDA approval in <strong>2016</strong>, which would fuel growth of the<br />
antidiabetic biosimilars market.<br />
Furthermore patent expiry of insulin aspart <strong>and</strong> insulin lispro is projected to propel growth of antidiabetic biosimilars market. Biosimilar<br />
insulin have potential to reduce diabetes treatment costs, increase accessibility of insulin treatment <strong>and</strong> exp<strong>and</strong> the number of insulin<br />
br<strong>and</strong>s.<br />
© Coherent market <strong>Insights</strong>. All Rights Reserved
REPORT DESCRIPTION<br />
Constraints for growth of the antidiabetic biosimilars market<br />
<strong>Biosimilars</strong> would have to face stringent regulatory requirements that would focus on their production<br />
before entering into major markets such as the U.S. While biosimilars have marked successful entry in<br />
the European markets, entry in the U.S. market is still a challenge due to stringent regulatory norms.<br />
Furthermore, biosimilars would need to gain favorable reimbursement to gain market traction.<br />
Increasing number of diabetes patients driving the antidiabetic biosimilars market globally<br />
Increasing incidence of diabetes, complexities in alternative diabetic therapies, <strong>and</strong> government<br />
incentives for introduction of low cost therapies are collectively creating a conducive environment for<br />
growth of the market. According to the International Diabetes Federation (IDF), there were around<br />
59.8 million diabetic patients in Europe in 2015. The market for antidiabetic biosimilar is expected to<br />
be high in near future in Asia Pacific due to increase in research activities related to antidiabetic<br />
products <strong>and</strong> supportive government funding. North America region is projected to represent a<br />
lucrative market for antidiabetic biosimilar in the near future, as prevalence of diabetes is increasing<br />
in this region. According to the International Diabetes Federation, in 2015, over 29.1 million people in<br />
the U.S. suffered from diabetes.<br />
Request report sample for more professional <strong>and</strong> technical insights:<br />
https://www.coherentmarketinsights.com/insight/request-sample/92<br />
© Coherent market <strong>Insights</strong>. All Rights Reserved
ABOUT COHERENT MARKET INSIGHTS<br />
ABOUT US<br />
Coherent <strong>Market</strong> <strong>Insights</strong> is a global market intelligence <strong>and</strong> consulting<br />
organization focused on assisting its plethora of clients achieve transformational<br />
growth by helping them make critical business decisions. We are headquartered in<br />
India, with an office at the global financial capital in the U.S. Our client base<br />
includes players from across all business verticals in over 150 countries worldwide.<br />
We are uniquely positioned to help businesses around the globe deliver practical<br />
<strong>and</strong> lasting results through various recommendations about operational<br />
improvements, technologies, emerging market trends <strong>and</strong> new working methods.<br />
We offer both customized <strong>and</strong> syndicated market research reports that help our<br />
clients create visionary growth plans to provide traction to their business. We<br />
meticulously study emerging trends across various industries at both the global<br />
<strong>and</strong> regional levels to identify new opportunities for our clientele.<br />
SERVICES<br />
INDUSTRY ANALYSIS<br />
MARKET INTELLIGENCE<br />
SERVICES<br />
CUSTOMIZED<br />
RESEARCH<br />
CONSULT STUDIES<br />
SYNDICATED RESEARCH<br />
COUNTRY SPECIFIC<br />
STUDIES<br />
© Coherent market <strong>Insights</strong>. All Rights Reserved
ABOUT COHERENT MARKET INSIGHTS<br />
Industries we cater<br />
SECTOR COVERAGE<br />
Healthcare<br />
BIOTECHNOLOGY CLINICAL DIAGNOSTIC HEALTHCARE IT<br />
MEDICAL DEVICES<br />
MEDICAL IMAGING<br />
Chemicals & Materials<br />
PHARMACEUTICAL<br />
Bulk Chemicals Advanced Materials Speciality <strong>and</strong> Fine<br />
Chemicals<br />
Green Chemicals<br />
Food Ingredients<br />
Cosmetic<br />
Ingredients<br />
Polymers &<br />
Resins<br />
© Coherent market <strong>Insights</strong>. All Rights Reserved
ABOUT COHERENT MARKET INSIGHTS<br />
KEY STATS<br />
100+<br />
<strong>Insights</strong> Published Per Year<br />
150+<br />
Consulting Projects Till Date<br />
125+<br />
Clients Worldwide Per Year<br />
RESEARCH SOLUTIONS<br />
CONSULT<br />
PROJECTS<br />
SURVEY<br />
RESEAR<br />
CH<br />
FEASIBILITY<br />
STUDIES<br />
EXCEL<br />
FORECAST<br />
DATABASE<br />
GLOBAL<br />
REPORTS<br />
COUNTRY<br />
ANALYSIS<br />
CUSTOMIZED<br />
SOLUTIONS<br />
COMPETITIVE<br />
ASSESSMENT<br />
110+<br />
Analysts <strong>and</strong> Contract Consultants<br />
TECHNOLOGY<br />
SNIPPETS<br />
Coherent <strong>Market</strong> <strong>Insights</strong> excels at offering unmatched actionable market intelligence across various industry verticals, including<br />
chemicals, healthcare, <strong>and</strong> food & beverages, to name a few. We implement holistic market research methodology in order to result in<br />
the best possible market research reports across various industries worldwide. Based on our unmatched expertise across various<br />
industries—no matter how large or small, how complex or unique—we help our clients achieve better outcomes with uniquely<br />
designed <strong>and</strong> highly customized solutions. Our coverage includes insights that help our clients ensure sustained growth in developed<br />
markets <strong>and</strong> also key inputs to help them tap into emerging markets <strong>and</strong> exploit the plethora of opportunities posed therein.<br />
© Coherent market <strong>Insights</strong>. All Rights Reserved
THANK YOU<br />
To know more about us, visit our website:<br />
www.coherentmarketinsights.com<br />
For sales queries or new topics email us on:<br />
sales@coherentmarketinsights.com<br />
For other queries contact:<br />
Mr. Shah<br />
(Manager - Business Development)<br />
Coherent <strong>Market</strong> <strong>Insights</strong><br />
sales@coherentmarketinsights.com<br />
+1-206-701-6702<br />
© Coherent market <strong>Insights</strong>. All Rights Reserved
Change language